ATE539748T1 - GLUCOKINASE ACTIVATORS - Google Patents

GLUCOKINASE ACTIVATORS

Info

Publication number
ATE539748T1
ATE539748T1 AT07716991T AT07716991T ATE539748T1 AT E539748 T1 ATE539748 T1 AT E539748T1 AT 07716991 T AT07716991 T AT 07716991T AT 07716991 T AT07716991 T AT 07716991T AT E539748 T1 ATE539748 T1 AT E539748T1
Authority
AT
Austria
Prior art keywords
ifg
diseases
impaired
glucokinase activators
disorders
Prior art date
Application number
AT07716991T
Other languages
German (de)
Inventor
Thomas Aicher
Steven Boyd
Mark Chicarelli
Kevin CONDROSKI
Ronald Hinklin
Ajay Singh
Timothy Turner
Ferdinand Rustam
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of ATE539748T1 publication Critical patent/ATE539748T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
AT07716991T 2006-01-27 2007-01-24 GLUCOKINASE ACTIVATORS ATE539748T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76317306P 2006-01-27 2006-01-27
PCT/US2007/001956 WO2007089512A1 (en) 2006-01-27 2007-01-24 Glucokinase activators

Publications (1)

Publication Number Publication Date
ATE539748T1 true ATE539748T1 (en) 2012-01-15

Family

ID=38109991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07716991T ATE539748T1 (en) 2006-01-27 2007-01-24 GLUCOKINASE ACTIVATORS

Country Status (9)

Country Link
US (1) US8022222B2 (en)
EP (1) EP1986645B1 (en)
JP (1) JP5236499B2 (en)
CN (1) CN101437512A (en)
AT (1) ATE539748T1 (en)
CA (1) CA2637172A1 (en)
ES (1) ES2378704T3 (en)
TW (1) TW200740804A (en)
WO (1) WO2007089512A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431713B2 (en) * 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
CN101679405A (en) * 2007-03-23 2010-03-24 阵列生物制药公司 2-aminopyridine analogs as glucokinase activators
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
WO2009022179A2 (en) * 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
AU2008310097B2 (en) * 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
ES2531396T3 (en) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Process to prepare pyridinone compounds
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
PE20110598A1 (en) 2008-10-02 2011-08-31 Respivert Ltd INHIBITORS OF MITOGEN P38 ACTIVATED PROTEIN KINASE ENZYMES
US20110230467A1 (en) * 2008-11-21 2011-09-22 Astellas Pharma Inc. 4,6-diaminonicotinamide compound
US8299073B2 (en) 2008-12-11 2012-10-30 Respivert Ltd. P38 MAP kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
WO2011124930A1 (en) 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
JP5787976B2 (en) 2010-04-08 2015-09-30 レスピバート・リミテツド Pyrazolyl urea as a P38 MAP kinase inhibitor
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
RS57375B1 (en) 2010-11-19 2018-08-31 Ligand Pharm Inc Heterocycle amines and uses thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
JPWO2012121314A1 (en) 2011-03-09 2014-07-17 第一三共株式会社 Dipyridylamine derivatives
CN102786517B (en) * 2011-05-18 2017-06-06 中国医学科学院药物研究所 The pyrimidine thiazole amines derivative of GK and PPAR double excitation activity
JP5748210B2 (en) * 2011-05-26 2015-07-15 日本化薬株式会社 Method for producing heterocyclic compound
JP2014517016A (en) * 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrimidine having BTK inhibitory activity and composition of pyrimidine compound and method for producing the same
EP2754654B1 (en) * 2011-09-05 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013086397A1 (en) * 2011-12-08 2013-06-13 Array Biopharma Inc. Urea compounds as gka activators
EP2850057A4 (en) 2012-05-18 2016-01-27 Amgen Inc Method for the preparation of thiadiazoles
TW201422606A (en) * 2012-11-08 2014-06-16 必治妥美雅史谷比公司 Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
US20160031874A1 (en) * 2013-03-13 2016-02-04 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
CN104610143A (en) * 2015-02-12 2015-05-13 佛山市赛维斯医药科技有限公司 Glucokinase activator containing nitroquinoline structure and application of glucokinase activator
JP6483272B2 (en) * 2015-02-17 2019-03-13 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ Compounds and methods for inducing browning of white adipose tissue
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
EP3307702A4 (en) 2015-06-11 2019-02-13 University of Pittsburgh - Of the Commonwealth System of Higher Education P62-zz chemical inhibitor
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
EP3848370A3 (en) * 2016-10-14 2021-09-15 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN113993859A (en) 2019-06-25 2022-01-28 益方生物科技(上海)股份有限公司 Heterocyclic compounds, methods of making and methods of using the same
CN110898049B (en) * 2019-11-29 2021-09-14 华中师范大学 Application of disulfide compound in preparation of medicine, FBP enzyme inhibitor and medicament for preventing and/or treating diabetes
WO2022147694A1 (en) * 2021-01-06 2022-07-14 Beijing Erai Therapeutics Co., Ltd. Aminoheteroaryl compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309241T1 (en) 1999-09-10 2005-11-15 Merck & Co Inc TYROSINE KINASE INHIBITORS
ES2255621T3 (en) * 2001-06-22 2006-07-01 MERCK & CO., INC. THYROSINE KINASE INHIBITORS.
WO2003078423A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
US20040023978A1 (en) 2002-07-24 2004-02-05 Yu Ren Active salt forms with tyrosine kinase activity
WO2004050645A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
CA2503715A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
PL378117A1 (en) * 2003-02-11 2006-03-06 Prosidion Limited Tri(cyclo) substituted amide compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
US7709475B2 (en) 2004-05-21 2010-05-04 Banyu Pharmaceutical Co., Ltd. Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton
EP1858879B1 (en) 2005-01-14 2012-06-06 Gilead Connecticut, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity
EP1841431A4 (en) * 2005-01-26 2009-12-09 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090233896A1 (en) * 2005-06-09 2009-09-17 Arrington Kenneth L Inhibitors of checkpoint kinases

Also Published As

Publication number Publication date
ES2378704T3 (en) 2012-04-17
EP1986645B1 (en) 2012-01-04
CN101437512A (en) 2009-05-20
JP5236499B2 (en) 2013-07-17
US8022222B2 (en) 2011-09-20
WO2007089512A1 (en) 2007-08-09
JP2009524670A (en) 2009-07-02
TW200740804A (en) 2007-11-01
EP1986645A1 (en) 2008-11-05
CA2637172A1 (en) 2007-08-09
US20090247526A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
ATE539748T1 (en) GLUCOKINASE ACTIVATORS
MY180558A (en) Pyridin-2-yl-amino-1,2,4- theiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
ATE521608T1 (en) GLUCOKINASE ACTIVATORS
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12016501607A1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
NO20090064L (en) Pyrasols as glucokinase activators
NO20064929L (en) Sulfonamide-thiazole pyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
EA201101187A1 (en) ANTI-DIABETIC MEDICINES CONTAINING DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONAL IN COMBINATION WITH OTHER ANTI-DIABETIC MEANS
TW200745037A (en) Organic compounds
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
MX2010001560A (en) Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor.
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
MX2007007174A (en) Cycloalkylamine derivatives.
NO20072608L (en) Biaryloksymetylarenkarboksylsyrer
BRPI0407620A (en) Aryl and heteroaryl derivatives substituted as glucose metabolism modulators and prophylaxis and treatment of their disorders
MX2007005590A (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof.
MX2009005935A (en) Chemical compounds and uses.
MY152037A (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
NO20074943L (en) Roflumilast for the treatment of diabetes mellitus
MY160123A (en) Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
MX2009009416A (en) Benzimidazole derivatives and methods of use thereof.
TW200631580A (en) Substituted benzoquinolizine derivatives
UY31352A1 (en) GLUCOCINASE ACTIVATORS
CY1116557T1 (en) PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLI PRODUCTS AS GLYCOKINASE INHIBITORS FOR THE TREATMENT OF DIABETES